ホーム
マーケット
チャート&アイデア
Algo
ニュース
Store
ブローカー
ダウンロード
経済指標カレンダー
取引シグナル
Webターミナル
「
/
」を入力して検索:@user、$symbol
検索
ログイン
アカウントを作成
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ASND
#7008
Ascendis Pharma A/S American Depositary Shares
233.500
0
+5.33%
セクター:
ベース:
利益通貨:
日中レンジ
1年のレンジ
1日の変化
+5.33%
月次変化
-2.17%
6か月変化
+13.86%
1年の変化
+13.86%
以前の終値
221.690
0
Open
233.660
0
Bid
Ask
Low
233.500
0
High
233.660
0
ボリューム
47
マーケット
株
ヘルスケア
ASND
Open full chart
Financials
Overview
明細書
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
53.75 M
56.94 M
57.15 M
57.71 M
60.69 M
61.98 M
237.53 M
Valuation ratios
Enterprise value
8.96 B
7.66 B
6.9 B
7.36 B
8.36 B
13.22 B
35.83 B
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
ニュース
FDA, 아스켄디스의 주 1회 연골무형성증 치료제 승인
FDA approves Ascendis’ once-weekly achondroplasia treatment
베른스타인, BioMarin 목표 주가 상향...밸류에이션 전망 긍정적
Ascendis Pharma, 연례 회의 일정 발표 및 2025년 보고서 공개
Ascendis Pharma schedules annual meeting and releases 2025 reports
RBC 캐피탈, 아센디스 파마에 ’Yorvipath’ 모멘텀 지속
RBC Capital reiterates Ascendis Pharma stock rating on Yorvipath momentum
캔터 피츠제럴드, Ascendis Pharma 목표 주가 $300으로 상향
Cantor Fitzgerald raises Ascendis Pharma stock price target to $300 on CNP franchise outlook
Stifel, Ascendis Pharma 목표가 325달러로 상향
Stifel raises Ascendis Pharma stock price target to $325 on Yorvipath growth
Baird, 경쟁사 데이터에도 BioMarin ’중립’ 유지